Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Luci vs PauseRX

Luci
Graded #106

Higher grade

vs+2.200000000000003
PauseRX
Graded #150

Lower grade

The verdict

Luci takes it — 70.7/100 to 68.5/100.

Luci grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Luci is a budget-focused GLP-1 telehealth platform offering compounded medications with upfront pricing: compounded semaglutide as low as $99/month and compounded tirzepatide as low as $145/month, plus oral…

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueLuci +17
83
66
Dose & formulationPauseRX +10
75
85
Clinical oversightPauseRX +12
71
83
Labs & monitoringLuci +1
53
52
FulfillmentLuci +9
70
61
Contract termsLuci +14
55
41
Luci · left barPauseRX · right bar

The numbers

MetricLuciPauseRX
WeighScore70.7/10068.5/100
GradeCC
Scorecard rank#106#150
Semaglutide$99/mo (starting dose, promotional rate, compounded)$199/mo
Tirzepatide$145/mo (starting dose, promotional rate, compounded)$249/mo (starting dose, compounded)
CoverageCoverage not publishedCoverage not published
Brand-name accessCompounded onlyYes
Oral / sublingualYesInjection only
Luci

Graded #106 · C

Strengths

  • Budget-friendly compounded GLP-1 pricing (compounded semaglutide as low as $99/month, tirzepatide as low as $145/month)
  • Multiple formats: compounded semaglutide and tirzepatide injections plus oral semaglutide and tirzepatide pill kits
  • Upfront pricing with no insurance required and a fast 3-minute questionnaire to start
  • Care delivered through DrTelx, an independent US telehealth medical group, with ongoing support and dose optimization
  • HIPAA-compliant platform with a large self-reported member base (50,000+)

Where it loses points

  • Compounded medications are not FDA-approved for weight loss (the site discloses this) — not brand Wegovy, Ozempic, Zepbound, or Mounjaro
  • Available only in select U.S. states, and the full state list is not published
  • The compounding pharmacy partner is not named
  • Headline prices are 'as low as' rates (asterisked) — your actual monthly cost may be higher
  • No LegitScript certification displayed; marketing leans heavily on testimonials
PauseRX

Graded #150 · C

Strengths

  • Names its 503A pharmacy partner (Strive Pharmacy, Gilbert AZ) — buyers can independently verify its licensure
  • Names its physician network (Beluga Health) — you can research the clinical platform handling your prescriptions
  • Publishes the FDA compounded-medication disclaimer
  • Corporate legal entity disclosed (PauseRX, Inc.) — uncommon for direct-to-consumer GLP-1 platforms
  • Flat $199 'all doses' compounded semaglutide pricing — no per-tier escalation

Where it loses points

  • States served not listed — site claims nationwide, but you must contact support to confirm availability
  • Restrictive cancellation policy — orders can't be changed or canceled once submitted, and medications can't be returned
  • No named medical director (Beluga Health is the network, not a named MD)
  • LegitScript certification number not shown — badge only, so no direct lookup
  • Insurance not accepted — cash-pay only; HSA/FSA eligibility not confirmed

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard